PolyMedix Inc. Announces Successful Meeting With FDA for Brilacidin

Published: Nov 16, 2012

RADNOR, Pa., Nov. 16, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company dedicated to developing novel treatments for infectious diseases with defensin-mimetic antimicrobial agents, today announced that it had a Type B meeting with the Division of Anti-Infective Products of the United States Food and Drug Administration (FDA). As a result of the meeting, PolyMedix has direction with respect to the design and conduct of its planned Phase 2B dose-optimization clinical trial using brilacidin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by Staphylococcus aureus (including MRSA) and Streptococcus pyogenes.

Back to news